Heart Failure Study Guide

Anatomy and Path of Blood Flow Through the Heart

• The sequential flow of blood through the cardiovascular system follows a definitive 13-step path moving between systemic and pulmonary circulation:

  1. Superior and Inferior Vena Cava: Deoxygenated blood returns from the systemic circulation of the upper body (superior vena cava) and lower body (inferior vena cava).

  2. Right Atrium: Deoxygenated blood enters the right atrium from the vena cavae.

  3. Tricuspid Valve: Blood passes from the right atrium through the tricuspid valve into the right ventricle.

  4. Right Ventricle: Receives deoxygenated blood and contracts to pump it forward.

  5. Pulmonary Valve: Blood is ejected through the pulmonary valve into the pulmonary artery trunk.

  6. Pulmonary Arteries: Right and left pulmonary arteries transport deoxygenated blood away from the heart into the lungs.

  7. Lungs: Gas exchange occurs within the pulmonary capillary beds; carbon dioxide is released and oxygen is absorbed.

  8. Pulmonary Veins: Oxygenated blood returns from the right and left lungs via four pulmonary veins into the heart.

  9. Left Atrium: Receives oxygen-rich blood from the pulmonary veins.

  10. Mitral Valve: Blood flows from the left atrium through the mitral (bicuspid) valve into the left ventricle.

  11. Left Ventricle: High-pressure chamber that receives oxygenated blood and pumps it into systemic circulation.

  12. Aortic Valve: Blood is ejected through the aortic valve into the main aorta.

  13. Aorta: Distributes oxygenated blood to all systemic tissue beds and organs throughout the body.

Overview of Heart Failure

• Definition: Heart failure (HF) is a clinical syndrome resulting from the inability of the heart to provide sufficient blood volume to meet the metabolic and oxygen demands of the body's tissues and organs.

• Etiology: Develops as a consequence of a primary myocardial insult that compromises structural integrity or cardiac pumping capacity.

• Physiological Consequences: A reduction in cardiac output (CO) initiates a cascade of systemic impairment:

  • Decreased tissue perfusion

  • Impaired pulmonary and systemic gas exchange

  • Fluid volume imbalance (vascular congestion or systemic edema)

  • Markedly reduced functional physical capacity

• Epidemiology: Heart failure represents the single most common reason for hospital admission among adults over 65 years of age.

Risk Factors and Underlying Causes

• Primary Risk Factors:

  • Hypertension (HTN): Along with CAD, constitutes the most common direct risk factor for HF development.

  • Coronary Artery Disease (CAD): Leading contributor to myocardial ischemia and ventricular dysfunction.

• Secondary Etiologies:

  • Congenital Cardiac Abnormalities: Structural deficits existing from birth.

  • Infectious and Inflammatory Conditions: Inflammatory processes affecting the myocardium or endocardium (e.g., myocarditis).

  • Cardiac Dysrhythmias: Persistent tachyarrhythmias or bradyarrhythmias disrupting effective pumping mechanics.

  • Toxins: Direct cardiotoxic substances including alcohol, illicit drugs, and specific chemotherapeutic agents.

  • Comorbidities: Co-existing chronic medical conditions significantly compound overall clinical risk.

Determinants of Cardiac Output

• Definition of Cardiac Output (CO): The net volume of blood pumped by the ventricles per minute. Normal resting cardiac output ranges from $4-8\,L/min$.

• Regulatory Factors: Any structural or functional interference with the normal physiological mechanisms regulating cardiac output can directly precipitate heart failure.

• Mathematical Formula:   $CO = SV \times HR$   where $CO$ is Cardiac Output, $SV$ is Stroke Volume, and $HR$ is Heart Rate.

• Stroke Volume (SV): The specific volume of blood ejected by the left ventricle with each individual heartbeat.

• Four Primary Determinants of Stroke Volume and Cardiac Output:

  1. Preload: The volume of blood in the ventricles at the end of diastole, determining the degree of myocardial stretch prior to contraction.

  2. Afterload: The resistance or systemic vascular pressure against which the left ventricle must pump to eject blood.

  3. Myocardial Contractility: The intrinsic contractile force generated by the myocardium for a given preload, independent of loading conditions.

  4. Heart Rate (HR): The frequency of ventricular cardiac contractions per minute.

Classification by Ejection Fraction and Ventricular Dysfunction

• Left-sided heart failure is the most common form of heart failure.

• Ejection Fraction (EF): The percentage of total end-diastolic blood volume present in the left ventricle (LV) that is pumped out of the LV with each subsequent systolic contraction.

• Normal Range: Normal left ventricular ejection fraction (LVEF) is $55\%-65\%$

Heart Failure with Reduced Ejection Fraction (HFrEF / Systolic Heart Failure)

• Pathophysiological Defect: Primary defect in ventricular systolic function characterized by compromised LV myocardial contraction.

• Diagnostic EF Threshold: LVEF is generally $< 40\%$.

• Underlying Etiologies: Inability of the cardiac muscle to contract effectively, pathologically elevated afterload, dilated or ischemic cardiomyopathy, and structural/mechanical defects.

• Hemodynamic Sequence:

  • The LV fails to generate adequate pressure to eject blood forward through the aortic valve into systemic arterial circulation.

  • Blood remaining in the LV causes persistent volume overload and elevation of intraventricular pressures.

  • Blood backs up into the left atrium and subsequently into the pulmonary vasculature.

  • Increased pulmonary hydrostatic pressure forces fluid out of pulmonary capillaries into the lung interstitium and alveoli, culminating in pulmonary congestion and pulmonary edema.

Heart Failure with Preserved Ejection Fraction (HFpEF / Diastolic Heart Failure)

• Pathophysiological Defect: Primary defect in ventricular diastolic function characterized by impaired relaxation and restricted passive filling of the ventricles.

• Diagnostic EF Threshold: LVEF remains normal or preserved ($\ge 50\%$

• Underlying Etiologies: The LV muscle becomes abnormally stiff, hyperplastic, or noncompliant.

• Hemodynamic Sequence:

  • High filling pressures are required to maintain ventricular filling during diastole due to stiffness.

  • Reduced end-diastolic volume leads to diminished cardiac output despite normal contractile mechanics.

  • Elevated backpressure leads to systemic and pulmonary fluid congestion.

• Diagnosis: Confirmed by classic clinical signs and symptoms of heart failure occurring alongside normal LVEF (55\%-65\%$) and objective evidence of diastolic dysfunction on an echocardiogram or cardiac catheterization.\n\n# Right-Sided Heart Failure\n\n- **Pathophysiology:** The right ventricle fails to contract effectively, reducing blood flow to the lungs and causing fluid to back up into the systemic venous circulation.\n- **Systemic Clinical Manifestations:**\n - Peripheral edema (dependent pitting edema of feet, ankles, and legs)\n - Abdominal ascites (peritoneal fluid accumulation)\n - Hepatomegaly (liver enlargement from chronic venous congestion)\n - Jugular Venous Distention (JVD)\n- **Etiology:**\n - **Left-Sided Heart Failure:** The primary cause of right-sided heart failure (pulmonary congestion elevates right ventricular afterload).\n - **Isolated Causes:** Right ventricular infarction, acute pulmonary embolism (PE), and cor pulmonale (right ventricular failure resulting from severe chronic pulmonary disease).\n\n# Compensatory Mechanisms in Heart Failure\n\n- In response to declining cardiac output, systemic homeostatic mechanisms are triggered to restore tissue perfusion. Although initially beneficial, chronic activation promotes adverse structural changes and clinical deterioration.\n\n- **Neurohormonal Responses:**\n - **Renin-Angiotensin-Aldosterone System (RAAS):** Activated by reduced renal blood flow; promotes sodium and water retention alongside arterial vasoconstriction, increasing preload and afterload.\n - **Sympathetic Nervous System (SNS):** Increases epinephrine and norepinephrine release, elevating heart rate, myocardial contractility, and vascular resistance, which escalates myocardial oxygen consumption.\n - **Natriuretic Peptides (ANP & BNP):** Atrial Natriuretic Peptide (ANP) and B-type Natriuretic Peptide (BNP) are released in response to atrial and ventricular ballooning and wall stretch. They promote natriuresis, diuresis, and vasodilation to counteract RAAS and SNS actions.\n\n- **Ventricular Adaptations:**\n - **Dilation:** Progressive enlargement of cardiac chambers to accommodate elevated end-diastolic volumes and maintain stroke volume.\n - **Hypertrophy:** Increase in muscle mass and ventricular wall thickness in response to chronic pressure or volume strain.\n - **Remodeling:** Alteration in the size, shape, structure, and cellular organization of the ventricle over time, leading to progressive myocardial failure.\n\n# Complications of Heart Failure\n\n- **Pleural Effusion:** Transudation of fluid into the pleural cavity surrounding the lungs secondary to elevated pulmonary capillary hydrostatic pressure.\n- **Dysrhythmias and Dyssynchronous Contraction:** Structural tissue remodeling and chamber enlargement disrupt normal electrical conduction, causing lethal atrial or ventricular dysrhythmias and uncoordinated ventricular contraction.\n- **Hepatomegaly:** Venous engorgement of hepatic tissue leading to right upper quadrant pain, elevated liver enzymes, and impaired protein synthesis.\n- **Cardiorenal Syndrome:** Bidirectional dysfunction wherein cardiac failure causes renal hypoperfusion and kidney dysfunction, exacerbating fluid retention and cardiac workload.\n- **Anemia:** Chronic inflammatory disease states, altered erythropoietin secretion from kidney failure, and nutritional impairments cause reduced hemoglobin concentrations.\n\n# Diagnostic Evaluation\n\n- **History and Physical Examination (H & P):** Comprehensive clinical evaluation of fluid overload signs, systemic perfusion, risk factors, and functional limitations.\n- **B-type Natriuretic Peptide (BNP) Level:** Quantitative cardiac biomarker elevated in response to ventricular stretch; confirms heart failure diagnosis and indexes severity.\n- **Echocardiogram:** Primary imaging modality to measure LVEF, evaluate valve motion, assess wall thickness, and differentiate systolic versus diastolic dysfunction.\n- **Electrocardiogram (EKG) / Holter Monitor:** Detects underlying ischemia, dysrhythmias, conduction delays, or left ventricular hypertrophy.\n- **Chest X-Ray:** Visualizes cardiomegaly, interstitial edema, alveolar fluid, and pleural effusion.\n- **Cardiac Catheterization:** Measures intracardiac pressures, cardiac output, coronary anatomy, and diastolic filling abnormalities directly.\n- **Magnetic Resonance Imaging (MRI):** Provides detailed functional and anatomical visualization of myocardial viability, tissue scarring, and structural cardiomyopathies.\n- **Stress Testing:** Measures exercise tolerance and identifies stress-induced myocardial ischemia.\n- **6-Minute Walk Test:** Objective assessment of overall functional exercise capacity and response to ongoing medical interventions.\n\n# Acute Decompensated Heart Failure (ADHF)\n\n\n\n- **Clinical Presentation:** ADHF is characterized by a sudden or rapid escalation of heart failure symptoms alongside severe reduction in functional status, requiring emergency evaluation and hospital admission.\n- **Pathophysiological Manifestations:** Dominated by progressive pulmonary congestion and systemic intravascular volume overload:\n - **Shortness of breath and coughing:** Primary respiratory distress.\n - **Fatigue and tiredness:** Impaired systemic tissue oxygen delivery.\n - **Interstitial Edema:** Fluid fluid filtration into the lung interstitial matrix.\n - **Alveolar Edema:** Fluid inundation of pulmonary alveoli impairing gas exchange.\n - **Pulmonary Edema:** Life-threatening acute pulmonary congestion.\n - **Pleural Effusion:** Fluid collection within the pleural space surrounding the lungs.\n - **Ascites:** Abdominal swelling caused by fluid accumulation within the peritoneal cavity.\n - **Peripheral Edema:** Marked swelling in ankles, lower legs, and feet.\n - **Weakened Pumping Action:** Progressive loss of effective myocardial contraction.\n\n## Interventions for ADHF\n\n\n\n- **Continuous Monitoring:**\n - Serial vital signs measurement\n - Continuous oxygen saturation (SpO_2) monitoring\n - Daily weight measurement (standardized tracking of fluid shifts)\n - Strict Intake and Output (I/O) recording\n - Assessment of cognitive status and mentation (to detect cerebral hypoperfusion)\n - Continuous ECG rhythm strip monitoring\n- **Patient Positioning Strategies:**\n - **High Fowler's Position:** Elevating the head of the bed to upright position (60^\circ - 90^\circ$$).

  • Physiological Rationale: Depresses the diaphragm inferiorly into the abdominal space and relaxes abdominal respiratory muscles, optimizing lung expansion and improving ventilation mechanics.

  • Leg Placement: Positioning lower extremities horizontally or dangling over the side of the bed reduces venous return (preload) to the struggling right heart.

Drug Therapy for ADHF

• Diuretics: Intravenous loop diuretics (e.g., furosemide) rapidly reduce intravascular volume, systemic congestion, and preload.

• Vasodilators: Intravenous agents (e.g., nitroglycerin, nitroprusside) dilate capacitance vessels, reducing preload and afterload to improve cardiac performance.

• Morphine: Decreases anxiety, acts as a mild vasodilator to reduce preload and pulmonary pressures, and decreases the work of breathing.

• Positive Inotropes: Short-term intravenous administration (e.g., dobutamine, dopamine, milrinone) increases myocardial contractility in severe cardiogenic shock or profound systolic impairment.

Chronic Heart Failure Management

• Clinical Manifestations:

  • Chronic fatigue

  • Dyspnea (exertional dyspnea, orthopnea, paroxysmal nocturnal dyspnea)

  • Persistent cough

  • Tachycardia and palpitations

  • Persistent dependent edema

  • Alterations in Urine Output (UOP) (oliguria during day, nocturia at night)

  • Cutaneous changes (dusky appearance, lower leg hyperpigmentation, cold skin)

  • Neurological manifestations (memory loss, decreased focus, confusion)

  • Behavioral and mood alterations

  • Sleep disturbances and sleep-disordered breathing

  • Anginal chest pain

  • Progressive weight fluctuations (fluid gain or severe cardiac cachexia)

Interprofessional Care and Lifestyle Interventions

• Sodium Restriction: Strict dietary restriction of sodium intake to minimize fluid retention.

• Fluid Restriction: Indicated for severe hypervolemia or refractory hyponatremia.

• Daily Body Weight Protocol: Patient instruction on weighing every morning after voiding and prior to eating; tracking subtle volume increases.

• Supplemental Oxygen: Administered to correct persistent hypoxemia.

• Continuous Pulse Oximetry: Used during evaluation or pulmonary physical rehab.

• Cardiac Rehabilitation: Supervised exercise programs designed to build physical endurance safely.

Pharmacological Management of Chronic HF

• Angiotensin-Converting Enzyme (ACE) Inhibitors: Cornerstone therapy to inhibit RAAS, promote vasodilation, reduce afterload, and prevent adverse cardiac remodeling.

• Angiotensin II Receptor Blockers (ARBs): Indicated for patients intolerant to ACE inhibitors (e.g., due to intractable cough or angioedema).

• Diuretics: Routine oral maintenance diuretics to control fluid volume overload.

• Aldosterone Antagonists: Mineralocorticoid receptor blockers that reduce mortality, attenuate myocardial fibrosis, and preserve potassium.

• Beta-Blockers: Directly block sympathetic overactivation, decrease heart rate, prevent dysrhythmias, and reduce long-term cardiac mortality.

• Digitalis: Glycoside agent (digoxin) that enhances myocardial contractility and slows AV node conduction, useful in symptomatic HFrEF or concurrent atrial fibrillation.

Health Promotion and Advanced Surgical Interventions

• Valvular Repair or Replacement: Surgical repair or prosthetic valve replacement to eliminate underlying mechanical valve disorders.

• Coronary Revascularization: Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Grafting (CABG) to eliminate ischemic myocardium.

• Pacemaker and Cardiac Resynchronization Therapy (CRT): Biventricular pacemakers synchronized to restore dyssynchronous ventricular contractions.

• Implantable Cardioverter-Defibrillator (ICD): Device placed to continuously monitor rhythm and deliver shocks to terminate fatal ventricular dysrhythmias.

• Lifestyle Maintenance: Weight management programs, cardiac-safe exercise routines, low-sodium diets, and routine immunizations (influenza, pneumococcal) to mitigate infection-triggered decompensation.

End-Stage Heart Failure Management

• Continuous Inotrope Therapy: Long-term home intravenous infusions of positive inotropes (e.g., dobutamine, milrinone) to support end-stage palliation or bridge to transplantation.

• Mechanical Circulatory Support (MCS) Devices: Surgically implanted mechanical pumps designed to take over the pumping function of the heart:

  • Left Ventricular Assist Device (LVAD): Mechanical pump attached to the apex of the left ventricle and connected directly to the ascending aorta. Blood bypasses the weak left ventricle and is propelled directly into systemic arterial circulation. The internal device connects via an abdominal wall driveline to an external battery unit and computer controller worn on a harness.

• Heart Transplantation: Definitive surgical replacement of the diseased heart with a healthy donor heart for qualified end-stage candidates.

• Palliative and Hospice Care: Specialized interprofessional care focused on relief of severe distress, symptom mitigation, and end-of-life care planning for patients ineligible for transplantation or MCS.